StockData
Xenon Pharmaceuticals Inc. logo

Xenon Pharmaceuticals Inc. (XENE) company profile

XENENasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 7/30
$38.78−0.48 (-1.22%)

Close on Nov 17, 2026Market cap $3.76BP/E –Yield –

About Xenon Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

The biopharmaceutical company specializes in discovering, clinically developing, and commercializing therapeutics aimed at treating neurological and psychiatric conditions. Its primary focus is on advancing ion channel modulators, featuring its lead investigational candidate, azetukalner, a Kv7 potassium channel opener evaluated in late-stage clinical trials for focal onset seizures, primary generalized tonic-clonic seizures, major depressive disorder, and bipolar depression. Additional early-stage programs target sodium and potassium channels for indications including pain and Dravet syndrome, alongside partnered research initiatives for epilepsy. The organization designs its therapies for patients suffering from difficult-to-manage central nervous system disorders.

The company's clinical research spans multinational sites across several countries, with trials enrolling patients in regions including the United States and Japan. In addition, its business activities involve strategic cross-border collaborations and licensing agreements with global pharmaceutical partners to advance select candidates worldwide. The provided text does not state the location of the company's corporate headquarters.

Summary of the business section of Xenon Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
Xenon Pharmaceuticals Inc.
Founded
1996
Headquarters
Burnaby, British Columbia, Canada
Address
200 - 3650 Gilmore Way
Phone
(604) 484-3300
Employees
370, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
A1
Fiscal year ends
December 31
Auditor
KPMG LLP, Vancouver, Canada

Stock & identifiers

Ticker
XENE
Exchange
Nasdaq
IPO date
Nov 5, 2014
Shares outstanding
97M, Aug 3, 2026
Public float
$2.40B, Jun 30, 2025
Filer category
Large accelerated filer
SEC CIK
1582313
CUSIP
98420N105
ISIN
CA98420N1050
FIGI
BBG0073DM784
Share class FIGI
BBG002VBMLS5
LEI
549300XV44Q9Z1MIPQ03
EIN
98-0661854

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Ian MortimerPRESIDENT & CEO, Director64,223
Thomas Patrick KellyChief Financial Officer22,500
Christopher John KenneyChief Medical Officer2
Andrea DiFabioChief Legal Officer7,301
Darren S. ClineChief Commercial Officer0
Sherry AulinChief Financial Officer0
Dawn SvoronosDirector31,373
Steven GannonDirector1,870
Gillian CannonDirector1,455
Gary PatouDirector29,798
Elizabeth A. GarofaloDirector2,645
Justin D. GoverDirector2,645
Patrick MachadoDirector2,645

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$9.22M$11.49M$3.57M$291$120
FY2024$9.80M$4.35M$4.14M$255$91
FY2023$10.12M$13.87M$3.06M$299$92
FY2022$9.23M$13.95M$3.18M$256$89
FY2021
Ian Mortimer
$3.89M$8.16M$1.97M$203$99
FY2021
Simon Pimstone
$4.12M$9.97M$1.97M$203$99

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Ian Mortimer
President and Chief Executive Officer
$786.00K–$1.77M$6.07M$550.20K$46.26K$9.22M-6%
Thomas Kelly
Chief Financial Officer
$114.55K–$1.26M$5.81M$51.55K$5.97K$7.24M–
Darren Cline
Chief Commercial Officer
$279.66K––$3.63M$125.85K$14.59K$4.05M–
Andrea DiFabio
Chief Legal Officer and Corporate Secretary
$510.00K–$532.20K$1.76M$229.50K$26.65K$3.06M-25%
Christopher Kenney
Chief Medical Officer
$565.00K–$532.20K$1.76M$254.25K$29.40K$3.15M-25%
Sherry Aulin
Former Chief Financial Officer
$330.44K$1.54K–––$24.47K$356.45K-91%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Nov 5, 2014
Offer price
$9.00
Securities offered
4,000,000
Gross proceeds
$36.00M
Exchange
Nasdaq
First trading day
Nov 5, 2014
First-day close
$10.50+16.7%
Lock-up ends (est.)
May 4, 2015

“The initial public offering price is $9.00 per common share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 370 employees, including 358 full-time and part-time regular employees, of which 183 are located in Canada and 175 are located in the U.S.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?